

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

WOCKHARDT BIO AG
Petitioner,

v.

JANSSEN ONCOLOGY, INC.,
Patent Owner.

Case No. IPR2016-01582
U.S. Patent No. 8,822,438 B2

**DECLARATION OF
CHRISTOPHER A. VELLTURO, PH.D.
IN SUPPORT OF PATENT OWNER RESPONSE**

Table of Contents

	Page(s)
I. INTRODUCTION AND SUMMARY.....	1
A. Qualifications and Experience	2
B. Evidence Considered.....	3
C. Summary of Opinions	3
II. BACKGROUND	6
A. Prostate Cancer.....	7
B. Demand for mCRPC Treatment.....	8
C. ZYTIGA®	9
D. The Patent-at-Issue	10
III. CONSIDERATION OF THE STONER DECLARATION.....	10
A. Overview of Dr. Stoner’s Contentions.....	11
B. The ’213 Patent as a Purported “Blocking Patent” Does Not Negate a Commercial Success Assessment	14
1. Overview	14
2. Development and License Attempts of Abiraterone Acetate.....	15
3. Dr. Stoner’s Contention that the ’213 Patent’s Licensing History is “insufficient to show applicability...to nexus” Does Not Withstand Scrutiny	17
C. Dr. Stoner’s Assessment of Nexus is Incomplete	21
D. Dr. Stoner’s Analysis Concerning the Relevance of ZYTIGA®’s “Unexpected Commercial Success” Is Misplaced and Incorrect.....	23

PROTECTIVE ORDER MATERIAL

E.	Dr. Stoner’s Mischaracterization of ZYTIGA®’s Marketplace Performance.....	25
IV.	AFFIRMATIVE ASSESSMENT.....	31
A.	Evaluation of Marketplace Success	31
B.	ZYTIGA®’s Commercial Success Is Due in Significant Part to the Claims of the ’438 Patent	36
1.	The ’438 Patent Covers the Only FDA-Approved Use of ZYTIGA®.....	37
2.	Physicians Value ZYTIGA® – The Combination of Abiraterone Acetate and Prednisone – for its Therapeutic Survival Benefit	37
3.	ZYTIGA®’s Commercial Success Is Not Attributable to Excessive Marketing Spend Levels	41
4.	ZYTIGA®’s Commercial Success Is Not Due to Aggressively Low Pricing.....	43
V.	CONCLUSION.....	44

PROTECTIVE ORDER MATERIAL

I, Christopher A. Velluro, hereby declare and state as follows:

I. INTRODUCTION AND SUMMARY

1. I have been retained as a consultant on behalf of Janssen Oncology, Inc. (“Janssen”), the patent owner in the present proceeding. I understand that the petition names Wockhardt Bio AG (“Wockhardt” or “petitioner”). I have no financial interest in, or affiliation with, the petitioner or the patent owner. Quantitative Economic Solutions, LLC, a consulting firm of which I am the founder and president, is being compensated for my work at my usual and customary hourly consulting rate of \$850.¹ QES’s compensation is not dependent upon the outcome of, or my testimony in, the present *inter partes* review or any litigation proceedings.

2. I have been asked to evaluate the analyses and conclusions put forth on behalf of the petitioner by Dr. Robert D. Stoner in his declaration (“the Stoner Declaration”).² I have also been asked to independently evaluate the commercial success of the combination therapy of abiraterone acetate and prednisone –

¹ QES is also compensated for the time spent on this matter by persons working at my direction. Those rates are lower than my hourly rate.

² Declaration of Robert D. Stoner, Ph.D., August 9, 2016 (Ex. 1077).

PROTECTIVE ORDER MATERIAL

marketed by Janssen as ZYTIGA®³ – and the extent to which ZYTIGA®’s commercial success is causally linked to the patent claims in U.S. Patent No. 8,822,438 B2 (“the ’438 patent” or the “Patent-at-Issue”).

A. Qualifications and Experience

3. My qualifications and experience relevant to the issues in this proceeding are summarized below. My *curriculum vitae* is submitted herewith as Exhibit 2045.

4. I am the founder and president of Quantitative Economic Solutions, LLC, a microeconomic consulting firm. I received a Doctor of Philosophy degree (Ph.D.) in Economics from the Massachusetts Institute of Technology in Cambridge, Massachusetts in 1989. My fields of specialization include industrial organization and econometrics.

5. I have extensive experience in the valuation of intellectual property and in the assessment of economic injury/damages sustained as a result of

³ As used herein, unless otherwise stated, the term “ZYTIGA®” refers to ZYTIGA® therapy, *i.e.*, abiraterone acetate in combination with prednisone for the treatment of patients with metastatic castration-resistant prostate cancer. (*See Ex. 1052*).

PROTECTIVE ORDER MATERIAL

2

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.